Published in Lung Cancer on May 16, 2007
Lung Cancer Vaccine Plus Oral Dietary Supplement | NCT01829373
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.45
Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis (2011) 0.99
Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer (2014) 0.91
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol (2012) 0.89
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer (2010) 0.88
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother (2013) 0.87
Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. J Exp Clin Cancer Res (2011) 0.86
Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res (2014) 0.85
Survivin: a unique target for tumor therapy. Cancer Cell Int (2016) 0.84
Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J Transl Med (2011) 0.84
Improving lung cancer survival; time to move on. BMC Pulm Med (2012) 0.82
Lung cancer vaccines. Cancer J (2011) 0.82
MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. Int J Cancer (2010) 0.80
Dendritic Cell (DC) Vaccine in Mouse Lung Cancer Minimal Residual Model; Comparison of Monocyte-derived DC vs. Hematopoietic Stem Cell Derived-DC. Immune Netw (2012) 0.79
Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. PLoS One (2017) 0.77
Immunobiology of dendritic cells. Annu Rev Immunol (2000) 23.65
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
Reciprocal control of T helper cell and dendritic cell differentiation. Science (1999) 7.28
Multidisciplinary management of lung cancer. N Engl J Med (2004) 7.13
T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today (1999) 4.49
Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med (1996) 3.30
Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol (2003) 3.03
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol (1998) 2.27
Part I: Vaccines for solid tumours. Lancet Oncol (2004) 1.61
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer (2001) 1.52
Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol (2005) 1.48
Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol (2004) 1.18
Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol (2005) 1.11
The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Clin Exp Allergy (1999) 1.11
Distinct maturation of, but not migration between, human monocyte-derived dendritic cells upon ingestion of apoptotic cells of early or late phases. J Immunol (2004) 1.08
Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother (2003) 1.07
Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer (2001) 1.05
Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry. J Immunol Methods (2004) 0.99
Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer (2001) 0.95
Vaccines for lung cancer. J Thorac Oncol (2006) 0.86
Dendritic cell maturation induced by delivery of ultraviolet-mediated apoptotic colorectal cancer cell lines. Anticancer Res (2003) 0.81
Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans. Blood (2011) 1.35
Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol (2004) 1.18
Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med (2005) 1.13
Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics (2004) 1.05
Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J Immunol Methods (2002) 0.97
Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev (2003) 0.92
Vaccines for lung cancer. J Thorac Oncol (2006) 0.86
Immunotherapy for lung cancer. Proc Am Thorac Soc (2009) 0.82
Issues concerning the large scale cryopreservation of peripheral blood mononuclear cells (PBMC) for immunotherapy trials. Cryobiology (2007) 0.79
Pilot study of 1650-G: a simplified cellular vaccine for lung cancer. J Thorac Oncol (2011) 0.79
Induction of cyclo-oxygenase-2 in non-small cell lung cancer cells by adenovirus vector information. Chest (2002) 0.78
The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer (2005) 0.78
Identification of HLA-CW3, GNAS and IMPA as cytotoxic T-lymphocyte (CTL) target antigens using an allogeneic mixed lymphocyte tumor cell culture (MLTC) system and subsequent cDNA library screening. Cancer Biother Radiopharm (2007) 0.75